Angiogenesis is a hallmark of cancer and is required for tumor growth and progression.
Antiangiogenic therapy has been revolutionarily developing and was approved for the …

The success of anticancer therapy is usually limited by the development of drug resistance.
Such acquired resistance is driven, in part, by intratumoural heterogeneity—that is, the …

The epithelial-to-mesenchymal transition (EMT) plays a critical role during normal
development and in cancer progression. EMT is induced by various signaling pathways …

Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops
resistance to chemotherapy. An unresolved question is whether resistance is caused by the …

Metastasis is the major cause of cancer-related deaths; therefore, the prevention and
treatment of metastasis are fundamental to improving clinical outcomes. Epithelial …

The success of immune checkpoint blockade in patients with a wide variety of malignancies
has changed the treatment paradigm in oncology. However, combination therapies with …

Sorafenib is an oral multikinase inhibitor that suppresses tumor cell proliferation and
angiogenesis and promotes tumor cell apoptosis. It was approved by the FDA for the …

The epithelial-to-mesenchymal transition (EMT) occurs during normal embryonic
development, tissue regeneration, organ fibrosis, and wound healing. It is a highly dynamic …

The epithelial–mesenchymal transition (EMT) is a developmental program that enables
stationary epithelial cells to gain the ability to migrate and invade as single cells. Tumor cells …

Tumors can be depicted as wounds that never heal, and are infiltrated by a large array of
inflammatory and immune cells. Tumor‐associated chronic inflammation is a hallmark of …